Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811667 | 0.90 | CYP3A4 (0.32) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16437152 | 0.90 | CYP3A4 (0.32) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17811669 | 0.89 | RXRA (0.31) | CYP3A4CYP2C9 | |
| SCHEMBL17804255 | 0.89 | CYP3A4 (0.32) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL16437158 | 0.89 | CYP3A4 (0.31) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17796908 | 0.88 | CYP3A4 (0.32) | CYP3A4CYP2C9 | |
| SCHEMBL16437151 | 0.87 | HCRTR1 (0.31) | — | |
| SCHEMBL17811653 | 0.87 | ADORA3 (0.32) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17811679 | 0.87 | CYP3A4 (0.37) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17811663 | 0.86 | CYP3A4 (0.31) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | CYP51A1, CYP4F11, CYP1B1 | CYP3A4 39/4885CYP2C9 197/4885CYP1A2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.